Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluo-Pred-Iver for Mild COVID-19
NCT05283954Phase 3Withdrawn
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of fluoxetine, prednisolone and CHILD-IVITAB in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoints: Proportion of composite endpoint of moderate, severe or critical COVID-19, ED attendance, hospitalization, or death at 14 days and SARS-CoV-2 viral load reduction at 7 days. Planned start May 2022; status: withdrawn.
02
Drugs
fluoxetineprednisoloneCHILD-IVITAB
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05283954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283954.